Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Legal Studies
Investigating The Potential And Pitfalls Of Ev-Encapsulated Micrornas As Circulating Biomarkers Of Breast Cancer, Brian M. Moloney, Katie E. Gilligan, Doireann P. Joyce, Clodagh P. O'Neill, Killian P. O'Brien, Sonja Khan, Claire L. Glynn, Ronan M. Waldron, Ciarán M. Maguire, Emma Holian, Erin Naughton, Mohamed Elhadi, Andrea B. Grealish, Carmel Malone, Emma Mcdermott, Peter Dockery, Thomas Ritter, Adriele Prina-Mello, Michael J. Kerin, Róisín M. Dwyer
Investigating The Potential And Pitfalls Of Ev-Encapsulated Micrornas As Circulating Biomarkers Of Breast Cancer, Brian M. Moloney, Katie E. Gilligan, Doireann P. Joyce, Clodagh P. O'Neill, Killian P. O'Brien, Sonja Khan, Claire L. Glynn, Ronan M. Waldron, Ciarán M. Maguire, Emma Holian, Erin Naughton, Mohamed Elhadi, Andrea B. Grealish, Carmel Malone, Emma Mcdermott, Peter Dockery, Thomas Ritter, Adriele Prina-Mello, Michael J. Kerin, Róisín M. Dwyer
Forensic Science Publications
Extracellular vesicles (EVs) shuttle microRNA (miRNA) throughout the circulation and are believed to represent a fingerprint of the releasing cell. We isolated and characterized serum EVs of breast tumour-bearing animals, breast cancer (BC) patients, and healthy controls. EVs were characterized using transmission electron microscopy (TEM), protein quantification, western blotting, and nanoparticle tracking analysis (NTA). Absolute quantitative (AQ)-PCR was employed to analyse EV-miR-451a expression. Isolated EVs had the appropriate morphology and size. Patient sera contained significantly more EVs than did healthy controls. In tumour-bearing animals, a correlation between serum EV number and tumour burden was observed. There was no significant relationship …
Screening Of Exosomal Micrornas From Colorectal Cancer Cells, Cillian Clancy, Sonja Khan, Claire L. Glynn, Emma Holian, Peter Dockery, Pierce Lalor, James A.L. Brown, Myles Joyce, Michael J. Kerin, Roisin M. Dwyer
Screening Of Exosomal Micrornas From Colorectal Cancer Cells, Cillian Clancy, Sonja Khan, Claire L. Glynn, Emma Holian, Peter Dockery, Pierce Lalor, James A.L. Brown, Myles Joyce, Michael J. Kerin, Roisin M. Dwyer
Forensic Science Publications
BACKGROUND: Cells release extracellular membrane vesicles including microvesicles known as exosomes. Exosomes contain microRNAs (miRNAs) however the full range within colorectal cancer cell secreted exosomes is unknown. OBJECTIVE: To identify the full range of exosome encapsulated miRNAs secreted from 2 colorectal cancer cell lines and to investigate engineering of exosomes over-expressing miRNAs. METHODS: Exosomes were isolated from HCT-116 and HT-29 cell lines. RNA was extracted from exosomes and microRNA array performed. Cells were engineered to express miR-379 (HCT-116-379) or a non-targeting control (HCT-116-NTC) and functional effects were determined. Exosomes secreted by engineered cells were transferred to recipient cells and the …
Impact Of Tumour Epithelial Subtype On Circulating Micrornas In Breast Cancer Patients, Peadar S. Waters, Roisin M. Dwyer, Cathy Brougham, Claire L. Glynn, Deidre Wall, Peter Hyland, Maria Duignan, Mark Mcloughlin, John Newell, Michael J. Kerin
Impact Of Tumour Epithelial Subtype On Circulating Micrornas In Breast Cancer Patients, Peadar S. Waters, Roisin M. Dwyer, Cathy Brougham, Claire L. Glynn, Deidre Wall, Peter Hyland, Maria Duignan, Mark Mcloughlin, John Newell, Michael J. Kerin
Forensic Science Publications
While a range of miRNAs have been shown to be dysregulated in the circulation of patients with breast cancer, little is known about the relationship between circulating levels and tumour characteristics. The aim of this study was to analyse alterations in circulating miRNA expression during tumour progression in a murine model of breast cancer, and to detemine the clinical relevance of identified miRNAs at both tissue and circulating level in patient samples. Athymic nude mice received a subcutaneous or mammary fat pad injection of MDA-MB-231 cells. Blood sampling was performed at weeks 1, 3 and 6 following tumour induction, and …